Objective. Although the Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R) has become a widely used screener for aberrant opioid-related behavior in adults, the length of the instrument may limit its utility. The purpose of the current study was to develop a short form of the SOAPP-R by retaining as few items as possible while maximizing predictive accuracy.
Background
Although prevalence rates vary across studies, recent research suggests that a significant subgroup, between 21% and 29% [1] , of chronic pain patients on long-term opioid therapy may show evidence of aberrant opioidrelated behaviors. Aberrant opioid-related behaviors is a broad category of problematic behaviors that are generally related to misuse or abuse of medications, but also may include diversion activities (e.g., sharing or selling medications) and drug-seeking behaviors (e.g., losing prescription or running out early, seeking pain medicine from multiple providers, emergency department visits to obtain additional prescriptions). Identifying and monitoring chronic pain patients who may be at risk for such behaviors is critical in order to prevent misuse, abuse, addiction, overdose, and other substance-related adverse events [2] . Although patient demographic and clinical variables have been identified as potential predictors of abuse (e.g., younger age, history of childhood sexual abuse, etc.) [3] , they are not reliable indicators of aberrant opioid behaviors in general. Further, clinical judgment is likely insufficient and inaccurate in predicting problematic opioid-related behavior. For example, nationally representative survey data of primary care physicians revealed that many held incorrect beliefs about opioids (e.g., that abuse-deterrent formulations are less addictive), misuse (e.g., routes of administration), and diversion [4] . Consequently, self-report screening questionnaires, urine drug testing, observation, and structured interviews are sometimes used to determine which chronic pain patients may be at risk. However, these tools may be unavailable, unreliable, or have poor predictive power in accurately identifying patients who are at risk for aberrant opioid-related behavior [2] . For instance, while routine urine toxicology screening is often considered the "gold standard" for detecting current use, a positive screen does not necessarily predict future aberrant opioid-related behaviors [5] and an initial negative screen does not provide evidence that the patient will not exhibit problematic opioid-related behaviors in the future.
Self-report screening instruments are one potential viable method for obtaining a quick and inexpensive estimation of a patient's likelihood of exhibiting aberrant drug-related behaviors. Importantly, for a screener to be useful, it must 1) be sensitive enough to identify patients who are at risk, 2) have the ability to accurately discriminate between those patients who are and who are not likely to engage in problematic opioid-related behavior, and 3) predict aberrant opioid behavior.
One screening instrument that has shown promise in achieving these aims is the Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R) [6] . The original Screener and Opioid Assessment for Patients with Pain (SOAPP) [7] is a 14-item conceptually derived instrument intended to identify chronic pain patients who may be at risk for problematic long-term opioid use. In a validation study of the SOAPP, patients classified as high risk were found to be younger, were more likely to have been asked to undergo a urine screening, and had more abnormal urine screens than those chronic pain patients who were classified as low risk, providing support for predictive validity [9] . To increase predictive validity of the screener and to reduce face validity of its items, a revised version of the SOAPP was created in 2008 (SOAPP-R) [6] . This 24-item SOAPP-R was empirically derived and includes more "subtle" items (i.e., their relationship to the outcome is not immediately transparent to respondents) [6] . It has exhibited strong sensitivity (0.81) and specificity (0.68) in predicting aberrant behavior.
Although the SOAPP-R has become a widely used screener for aberrant opioid-related behavior in adults, the length of the instrument may limit its utility. Indeed, short forms of the SOAPP-R have been proposed. In 2016, Finkelman and colleagues explored the sensitivity and specificity of short forms of the SOAPP-R and found that a 12-item form exhibited sensitivity, specificity, and an area under the curve (AUC) equivalent to or surpassing those of the full 24-item SOAPP-R [10] . Finkelman and colleagues also explored the use of curtailment and stochastic curtailment to reduce the length of the SOAPP-R in computer-based administrations [11] . These researchers were able to reduce the average SOAPP-R length by as much as 26% and 65% while retaining sensitivity and specificity values equivalent to the full SOAPP-R using curtailment and stochastic curtailment, respectively. While these are important efforts in attempting to reduce the patient burden associated with taking a routine screening scale, Finkelman and colleagues [10, 11] used only the data set on which the original SOAPP-R was developed and cross-validated. Further, their approach used the arithmetic sum of the scores, so that each item is weighted the same toward a designation of high or low risk. For the present effort, on the other hand, we wanted to explore additional methods that included differential weighting of items that may ultimately lead to more effective use of computer administration of the screener, along with the addition of a larger data set containing more recently collected data. Therefore, we endeavored to continue to explore brief forms of the SOAPP-R across different and larger patient samples.
The purpose of this study was to select a subset of the SOAPP-R items that maximally predicts aberrant drug use behavior five months later. Specifically, the intention was to retain as few items as possible while maintaining the same levels of predictive accuracy as the full 24-item SOAPP-R.
Methods
This study was approved by the New England Institutional Review Board.
Participants
This study utilized retrospective data from the original SOAPP-R development study ("Sample 1" N ¼ 428) [6] , as well as new data ("Sample 2" N ¼ 127) [12, 13] . Participants were recruited from pain clinics in Massachusetts, Ohio, Pennsylvania, Indiana, and New Hampshire. Adult patients from participating treatment centers were eligible to participate if they were 1) receiving treatment for chronic noncancer pain and 2) were on a long-term opioid treatment regimen for pain. Approximately half of the total sample (N ¼ 555) was female (55.2%), and the majority of participants identified as Caucasian (83.6%). Participants ranged in age from 21 to 89 years (M ¼ 50.9, SD ¼ 12.2). Demographic information is presented in Table 1 .
Each participant completed the 24-item SOAPP-R and participated in a five-month follow-up visit, at which time 1) they completed the 42-item self-report Prescription Drug Use Questionnaire (PDUQ) [8, 14] , 2) their physician completed the Prescription Opioid Therapy Questionnaire (POTQ) [15] , and 3) a urine toxicology screen was completed (see the Aberrant Drug Behavior Index section).
Development and Validation of an Eight-Item SOAPP-R

Measures
SOAPP-R
The SOAPP-R [6] is a 24-item self-report screener that is intended to identify chronic pain patients who may be at risk for aberrant opioid behavior. Patients respond to each item using a five-point Likert-type rating scale (0 ¼ never to 5 ¼ very often). The SOAPP-R is scored by adding up the patient's response to each of the 24 items and comparing this response to a cutoff score. The SOAPP-R has exhibited adequate sensitivity (0.81) and specificity (0.68) in previous studies [6] .
Aberrant Drug Behavior Index
The Aberrant Drug Behavior Index (ADBI) is an outcome measure of aberrant opioid-related behaviors. In the current study, the ADBI was completed at follow-up in order to classify participants into one of two groups: those who had evidenced some aberrant medicationrelated behaviors and those who had not. As such, the ABDI was used as the criterion (or dependent variable in the logistic regression) against which SOAPP-R items were identified that had the strongest predictive validity and therefore should be retained for a short form. The ADBI is based on three separate tests: a self-report questionnaire (PDUQ), a physician-reported questionnaire (POTQ), and a urine toxicology screen. A patient is classified as being positive on the ADBI using a triangulation-of-data method such that 1) the PDUQ is positive and/or 2) the POTQ and urine screen are positive. More information about the ADBI can be found in Butler et al. (2008) and Butler et al. (2009) [6, 16] .
Data Analytic Strategy
Data analysis was carried out in the following steps: We 1) examined the frequency distributions for each of the 24 SOAPP-R items and the aberrant drug use variable; 2) identified the optimal set of SOAPP-R items that predict aberrant drug use behavior using the LASSO method [17] as the "selection" criterion in combination with the leave-one-out cross-validation (LOOCV) method [18] as the "stop" criterion through the GLMSELECT procedure in SAS in conjunction with content expertise; 3) employed logistic regression 1 to predict the probabilities of a positive SOAPP-R score from the subset of SOAPP-R items identified in step 2 using all data and using the LOOCV method; 4) generated receiver operating characteristic (ROC) curves for the (a) modelpredicted probabilities from the subset of items using all of the data, (b) model-predicted probabilities from the subset of items using LOOCV, and (c) the sum of all 24 SOAPP-R items to compare the AUC; 5) determined the cutoff point that optimized sensitivity and specificity for the model-predicted probabilities from the subset of items using all of the data. Analyses were performed using SAS 9.4 [19] .
Results
Frequency Distribution for the SOAPP-R and Aberrant Drug Use Variables
A careful examination of the distribution of the 24 SOAPP-R items revealed that all of the response options for all 24 items were selected by the respondents, providing some evidence that the five-point scale is appropriate for these items. In addition, the distribution of the item responses was positively skewed, with participants tending to endorse lower-frequency response options (e.g., never, seldom) over higher-frequency response options (e.g., often, always). Of the 555 participants, 36.6% (N ¼ 203) were classified as engaging in aberrant drug use behavior.
Subject-to-Sample Size Ratio
To determine the subject-to-sample size ratio when fitting a logistic regression, the numbers of nonevents (negative ADBI) and events (positive ADBI) are calculated, whereby the smaller number of the two is used as size of the sample. For these data, the number of events (N ¼ 203) was smaller than the number of nonevents (N ¼ 352), and therefore was used as the sample size. For these data, the subject-to-variable ratio was 203 (participants positive on aberrant drug use behavior-to-24 SOAPP-R items) or 8 subjects per predictor variable. Research has shown that a minimum subject-to-variable ratio of 5-to-1 in regression can produce stable and reasonably accurate estimates of the regression coefficients [20] . 
Item Selection
The subset of SOAPP-R items that maximally predicted aberrant drug use behavior was identified by employing the LASSO selection method offered in the GLMSELECT procedure in SAS 9.4. The stop criterion used for this selection method was LOOCV. Of the 24 SOAPP-R items, eight were identified before the selection method stopped ( Table 2 ). The content of this final subset of items (8) and the 16 items that were not retained was reviewed by doctoral-level experts (N ¼ 4) to determine whether any of the items that were dropped from the final model were essential to retain from a clinical perspective. Experts agreed that the final item pool was satisfactory.
ROC Curve Analyses
Results from the ROC curve analyses performed on the predicted probabilities 2 from the model, the predicted probabilities from the LOOCV data, and the 24-item total score data yielded AUCs of 0.79, 0.78, and 0.76, respectively. See Figure 1 for ROC curves for each year. An optimal cutoff point of 0.2979 on the predicted probabilities from all the data yielded a sensitivity of 0.74 and a specificity of 0.66. This cut-point is intended to identify patients who are at risk for misusing their prescription opioids (i.e., not using their medication as directed). Specifically, patients who scored below this cut-point can be classified as having no risk to slight risk, while patients who scored above the cut-point have nearly a 30% chance of exhibiting aberrant drug-related behaviors, suggesting moderate levels of risk. To provide clinicians with more information about patients' potential risk, we identified the sensitivity and specificity values associated with a cut-point of 0.5119. That is, these patients have greater than a 50% chance of engaging in aberrant drug-related behaviors, placing them into a category of high risk. This cut-point yielded a sensitivity of 0.46 and a specificity of 0.90.
Discussion
Given the serious societal and personal problems that have been associated with opioid analgesics and the continuing role that opioids may play in the treatment of chronic pain, having reliable and valid methods to predict aberrant drug-related behavior is critical. While the SOAPP-R has shown promise in accurately identifying those chronic pain patients who are at risk for having problems managing their opioids, its length (24 items) may preclude its application in busy practices, emergency departments, and other similar settings. While previous research using the same data set from which the original SOAPP-R was developed has arrived at various short forms, these results may be biased and highly sample-dependent. Therefore, the current study sought to reduce the length of the SOAPP-R by identifying a subset of items with the greatest predictive power using a different sample of chronic pain patients than the original validation study. Using advanced logistic regression models and employing cross-validation procedures, a final subset of eight items was identified. Importantly, ROC analyses revealed the AUC (essentially accuracy of prediction, whereby 1.0 represents perfect predictive accuracy and 
Figure 1
Receiver operating characteristic curves for model, cross-validation, and full 24-item Screener and Opioid Assessment for Patients with Pain-Revised total score.
Development and Validation of an Eight-Item SOAPP-R 0.5 represents 50% predictive accuracy; i.e., the test is no better than flipping a coin) for the SOAPP-8 to be superior to the AUC value generated by the full 24-item SOAPP-R, while reducing test length by 67%. Further, the sensitivity (the ability to identify patients who are at risk) and specificity (the ability to accurately discriminate between those patients who are and who are not likely to engage in problematic opioid-related behavior) of the SOAPP-8 were comparable with the full SOAPP-R. These results provide strong support for the predictive accuracy of the SOAPP-8.
Results from this study demonstrate how sophisticated statistical procedures such as advanced regression models can be employed to reduce instrument length while retaining predictive accuracy. This is largely due to the differential weighting of items and their response categories in the prediction algorithm. Subsequently, while administration of the SOAPP-8 can be completed by computer or paper and pencil, 3 the scoring of the SOAPP-8 requires a computer.
Consistent with several previous studies utilizing the SOAPP-R, a patient's classification of aberrant medication-related behavior at five-month follow-up was determined through a positive ABDI, a relatively comprehensive method for combining patient self-reported problematic behaviors with urine toxicology results and physician reports. The SOAPP-8's ability to predict misuse, abuse, addiction, or other constructs not addressed by the ADBI is unknown.
It may be useful here to reflect that since the development of the SOAPP-R and the ADBI measure, interest has increased in efforts to distinguish misuse and abuse. In a 2013 review by the Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT) Working Group-convened by the Analgesic, Anesthetic, and Addiction Clinical Trials, Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership [21] -misuse and abuse were differentiated by intention of the behavior. For these authors, misuse is the intentional use of an opioid in a nonprescribed way for a therapeutic reason, that is, to alleviate an aversive symptom or state. Abuse, on the other hand, is intentional use of an opioid in a nonprescribed manner for the express purpose of achieving a desirable psychological or physiological effect. The SOAPP-R and, correspondingly, the SOAPP-8 were not intended to differentiate a patient's intention for engaging in problematic behaviors, and as such are agnostic as to the patient's conscious intentions. We also assume that there may be other motivations involved when patients engage in aberrant behaviors, such as coercion by others [22] . Thus, it is better in this context to use the term aberrant opioid-related behavior to indicate the focus on the presence of behavioral problems only, which would include misuse and abuse, but other problematic behaviors as well.
It is further interesting to note that Finkelman and colleagues' [10] 12-item short-form of the SOAPP-R included seven of the eight items that were identified in the current study to be most highly predictive of aberrant drug-related behavior (SOAPP-R item 7, "How often have you been concerned that people will judge you for taking pain medication?", was not included in Finkelman et al.'s 12-item short form). The similarity in findings across these studies supports the utility of the seven SOAPP-R items in predicting aberrant drugrelated behavior. The differences in the short forms developed across these studies may be due to the addition of a more recent sample, and, as such, ours was not identical to the sample used by Finkelman et al. Another difference could be that the statistical methods used in this study selected items that accounted for greater variance in the dependent variable and, when considered as part of an algorithm, were more predictive than other items.
The current study incorporated patients with chronic noncancer pain who were recruited from treatment centers in several states. However, the predictive accuracy of the SOAPP-8 with other populations, such as teenagers or cancer patients, is unknown and may be evaluated in future research. In this study, patients were followed for five months and then evaluated for aberrant opioid-related behaviors. Certain health care providers may be interested in learning the SOAPP-8's predictive accuracy in identifying patients who evidence pain medication issues over shorter or longer periods of time. For example, in the field of dentistry, specialists such as oral surgeons are prescribing pain medications to potentially opioid-naïve patients (such as young adults who present for third molar extractions ["wisdom teeth"]). Therefore, having a brief screener that has high accuracy in predicting early signs of opioid-related problems three or four weeks after prescribing may be of particular interest to these prescribers.
Notes
1. The FIRTH correction to maximum likelihood estimation method was utilized to reduce bias [23] .
2. The probabilities were predicted from the weighted linear combination of the set of predictors (eight SOAPP-R items) entered into the logistic regression model.
3. Although the SOAPP-8 could be completed by paper and pencil, the responses would need to be entered into a computer in order to score the instrument.
